Peritoneal metastases, a significant challenge in advanced abdominal cancers, often lead to poor
prognosis due to widespread cancer cell dissemination, rendering systemic chemotherapy less
effective. We will investigate whether a novel nanotechnology-based single-dose therapy for postsurgical application can destroy residual cancer cells and stimulate anti-tumor immunity. We
hypothesize that the latter can be optimally achieve through three drug delivery phases: firstly,
oxaliplatin for killing cancer cells and generating a pool of tumor antigens; secondly, an
imidazoquinoline Toll-like receptor 7/8 agonist, activating immune cells to present these antigens;
and thirdly, immune checkpoint blocking antibodies to enhance cytotoxic T cell response and prevent
new metastases. We will utilizes supramolecular nanofiber hydrogels, capable of entrapping various
molecules, ensuring a controlled release of these drugs. Our focus is on investigate these hydrogels
for optimal drug release, maintaining therapeutic levels in the peritoneal cavity over time. This
approach not only aims to improve direct anti-tumor efficacy but also to reduce the systemic side
effects typically associated with chemotherapy.